PLC (AIM: 4BB) (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received ...

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma ...

On March 17, 2025, the government published a policy paper with an Action Plan for regulation and regulators, outlining how it intends to reform ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

The MHRA has introduced seven new CERSIs to modernise healthcare regulation and accelerate patient access to innovative ...

Seven new CERSIs came together to showcase how partnerships will modernise regulation in AI, clinical trials, and advanced therapies, bringing ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...

Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, today announces a positive opinion from the European Medicines Agency (EMA)’s Committee for ...

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and ...

4basebio PLC has been granted Good Manufacturing Practice (GMP) certification by the UK’s Medicines and Healthcare products ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...